Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR)

CERo Therapeutics (NASDAQ:CEROGet Free Report) and Atyr PHARMA (NASDAQ:ATYRGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Volatility & Risk

CERo Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Profitability

This table compares CERo Therapeutics and Atyr PHARMA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CERo Therapeutics N/A N/A -108.43%
Atyr PHARMA N/A -79.44% -59.16%

Valuation and Earnings

This table compares CERo Therapeutics and Atyr PHARMA”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CERo Therapeutics N/A N/A -$2.54 million N/A N/A
Atyr PHARMA $350,000.00 896.96 -$50.39 million ($0.94) -3.98

CERo Therapeutics has higher earnings, but lower revenue than Atyr PHARMA.

Analyst Ratings

This is a summary of current recommendations and price targets for CERo Therapeutics and Atyr PHARMA, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics 0 0 0 0 0.00
Atyr PHARMA 0 0 5 0 3.00

Atyr PHARMA has a consensus target price of $19.25, indicating a potential upside of 414.71%. Given Atyr PHARMA’s stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than CERo Therapeutics.

Insider and Institutional Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 18.0% of CERo Therapeutics shares are held by insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Atyr PHARMA beats CERo Therapeutics on 7 of the 10 factors compared between the two stocks.

About CERo Therapeutics

(Get Free Report)

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Atyr PHARMA

(Get Free Report)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Receive News & Ratings for CERo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CERo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.